OXiGENE, Inc. (NASDAQ:OXGN) reported interim results from a Phase II ovarian cancer study evaluating a combination of Zybrestat and bevacizumab. The two drugs passed a significant safety hurdle, said the company, with only one adverse event in 25 patients. OXiGENE will continue to enroll now that safety criteria has been met. Zybrestat (fosbretabulin) is also in trials evaluating its efficacy against Anaplastic Thyroid Cancer and Non-Small Cell Lung Cancer. OXGN is moving before the open today, up 35% on very few trades. Expect gains, but not at current levels; shares are likely to trade back with the opening bell.